Kairos Pharma (NYSEAMERICAN:KAPA) Shares Down 6.1% – Here’s Why

by · The Markets Daily

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA – Get Free Report) shares fell 6.1% during mid-day trading on Tuesday. The company traded as low as $0.4705 and last traded at $0.4740. 82,392 shares changed hands during trading, a decline of 31% from the average session volume of 119,966 shares. The stock had previously closed at $0.5050.

Kairos Pharma Price Performance

The firm has a market capitalization of $1.61 million, a price-to-earnings ratio of -0.24 and a beta of 1.85. The business has a 50 day moving average of $1.15 and a 200 day moving average of $2.87.

Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.42) earnings per share for the quarter. On average, sell-side analysts forecast that Kairos Pharma, Ltd. will post -2.59 EPS for the current fiscal year.

Kairos Pharma Company Profile

(Get Free Report)

Kairos Pharma, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies designed to address immune suppression and treatment resistance within the tumor microenvironment. The company’s research is centered on immuno-oncology approaches intended to improve the body’s ability to recognize and attack cancer cells. Kairos Pharma is developing a pipeline of investigational therapies, including antibody-based and small-molecule programs aimed at biological pathways associated with tumor growth, immune evasion and resistance to existing treatments.

Featured Articles